OncoMatch/Clinical Trials/NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Is NCT04104776 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Tulmimetostat and Enzalutamide for advanced solid tumor.
Treatment: Tulmimetostat · Enzalutamide — The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Tumor Agnostic
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mesothelioma
Prostate Cancer
Endometrial Cancer
Ovarian Cancer
Biomarker criteria
Required: ARID1A mutation
Required: ARID1A wild-type
Required: BAP1 loss
Allowed: EZH2 hotspot mutation
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — relapsed/refractory
relapsed following standard therapy or progressed through standard therapy or who have a disease for which no standard effective therapy exists
Must have received: systemic therapy — PTCL: at least 1 prior line; DLBCL: at least 2 prior lines
patients with PTCL must have at least 1 prior line of therapy and patients with DLBCL must have at least 2 prior lines of standard therapy
Must have received: active therapy — mesothelioma: at least 1 prior line
malignant pleural or peritoneal mesothelioma, and have progressed on at least 1 prior line of active therapy
Must have received: androgen-receptor signaling inhibitor — mCRPC: at least 1 prior
mCRPC...have progressed on at least 1 androgen-receptor signaling inhibitor
Must have received: taxane-based chemotherapy (cabazitaxel) — mCRPC: at least 1 prior (cabazitaxel, France only)
at least 1 taxane-based chemotherapy (cabazitaxel, France only)
Must have received: systemic platinum-based chemotherapy — endometrial carcinoma: at least one treatment line in advanced/recurrent disease
at least one treatment line with systemic platinum-based chemotherapy in advanced/ recurrent disease setting
Must have received: anti-PD-1 therapy — endometrial carcinoma: at least one treatment line
anti-programmed cell death protein 1 (PD-1)/ anti-programmed death-ligand 1 (PD-L1) therapy, either in combination or separately, unless these are contraindicated or are not locally accessible
Cannot have received: EZH2 inhibitor
Previous treatment with an EZH2 inhibitor is not allowed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Winship Cancer Institute of Emory University · Atlanta, Georgia
- University of Chicago Medical Center · Chicago, Illinois
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center · Baltimore, Maryland
- Massachusetts General Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04104776 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EZH2 inhibitor disqualifies patients from enrollment.
Does this trial require ARID1A?
Yes, ARID1A mutation is a required biomarker for enrollment.
Does this trial require ARID1A?
Yes, ARID1A wild-type is a required biomarker for enrollment.
Does this trial require BAP1?
Yes, BAP1 loss is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify